

# JORDAN

Number of new cases

**12 328**

Number of deaths

**6 458**

Number of prevalent cases (5-year)

**34 172**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	5 220 178	5 080 684	10 300 862
<b>Incidence*</b>			
Number of new cancer cases	5 694	6 634	12 328
Age-standardized incidence rate	149.9	157.6	152.6
Risk of developing cancer before the age of 75 years (cum. risk %)	15.7	15.9	15.7
Top 3 leading cancers (ranked by cases)**	Lung Colorectum Bladder	Breast Colorectum Thyroid	Breast Colorectum Lung
<b>Mortality*</b>			
Number of cancer deaths	3 453	3 005	6 458
Age-standardized mortality rate	94.5	75.5	84.3
Risk of dying from cancer before the age of 75 years (cum. risk %)	10.0	8.2	9.1
Top 3 leading cancers (ranked by deaths)**	Lung Colorectum Stomach	Breast Colorectum Leukaemia	Lung Breast Colorectum
<b>Prevalence*</b>			
5-year prevalent cases	14 518	19 654	34 172



## Top 5 most frequent cancers\*\*

**Males**




Total: 5 694

Rank	Cancer site	Number of cases	Percent
1st	Lung	853	15.0%
2nd	Colorectum	629	11.0%
3rd	Bladder	567	10.0%
4th	Prostate	468	8.2%
5th	Leukaemia	323	5.7%
-	Others	2 854	50.1%

Number of new cases in 2022, males, all ages

**Females**




Total: 6 634

Rank	Cancer site	Number of cases	Percent
1st	Breast	2 598	39.2%
2nd	Colorectum	645	9.7%
3rd	Thyroid	442	6.7%
4th	Leukaemia	296	4.5%
5th	Corpus uteri	271	4.1%
-	Others	2 382	35.9%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 12 328

Rank	Cancer site	Number of cases	Percent
1st	Breast	2 598	21.1%
2nd	Colorectum	1 274	10.3%
3rd	Lung	1 048	8.5%
4th	Bladder	638	5.2%
5th	Leukaemia	619	5.0%
-	Others	6 151	49.9%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	2 598	1	21.1	6.4	802	2	12.4	2.1	8 192	161.2
Colorectum	1 274	2	10.3	1.9	658	3	10.2	0.97	3 635	35.3
Lung	1 048	3	8.5	1.7	967	1	15.0	1.6	1 484	14.4
Bladder	638	4	5.2	1.0	252	9	3.9	0.39	1 979	19.2
Leukaemia	619	5	5.0	0.66	412	4	6.4	0.48	1 903	18.5
NHL	542	6	4.4	0.70	286	7	4.4	0.42	1 743	16.9
Thyroid	528	7	4.3	0.55	70	19	1.1	0.10	1 768	17.2
Prostate	468	8	3.8	1.8	154	12	2.4	0.28	1 078	20.7
Brain CNS	431	9	3.5	0.46	340	6	5.3	0.41	1 594	15.5
Stomach	413	10	3.4	0.63	348	5	5.4	0.54	674	6.5
Pancreas	289	11	2.3	0.46	282	8	4.4	0.45	361	3.5
Corpus uteri	271	12	2.2	0.93	83	17	1.3	0.29	932	18.3
Kidney	256	13	2.1	0.36	122	15	1.9	0.19	775	7.5
Ovary	240	14	1.9	0.66	159	11	2.5	0.51	711	14.0
Larynx	233	15	1.9	0.37	132	14	2.0	0.22	742	7.2
Hodgkin lymphoma	221	16	1.8	0.17	61	20	0.95	0.06	808	7.8
Liver	197	17	1.6	0.30	192	10	3.0	0.30	285	2.8
Multiple myeloma	175	18	1.4	0.28	136	13	2.1	0.24	500	4.9
Cervix uteri	133	19	1.1	0.34	84	16	1.3	0.24	401	7.9
Lip, oral cavity	104	20	0.84	0.14	48	22	0.74	0.07	300	2.9
Nasopharynx	100	21	0.81	0.12	57	21	0.88	0.07	321	3.1
Testis	94	22	0.76	0.12	11	26	0.17	0.02	350	6.7
Oesophagus	78	23	0.63	0.12	76	18	1.2	0.12	112	1.1
Gallbladder	66	24	0.54	0.11	47	23	0.73	0.08	96	0.93
Salivary glands	40	25	0.32	0.05	19	24	0.29	0.03	125	1.2
Melanoma	29	26	0.24	0.04	8	27	0.12	0.01	103	1.0
Mesothelioma	13	27	0.11	0.02	13	25	0.20	0.02	21	0.20
Kaposi sarcoma	13	27	0.11	0.02	3	31	0.05	0.00	25	0.24
Vulva	12	29	0.10	0.03	4	29	0.06	0.01	35	0.69
Vagina	11	30	0.09	0.03	7	28	0.11	0.02	29	0.57
Oropharynx	10	31	0.08	0.02	4	29	0.06	0.01	27	0.26
Hypopharynx	10	31	0.08	0.01	3	31	0.05	0.00	20	0.19
<b>All cancers</b>	<b>12 328</b>	-	-	<b>15.7</b>	<b>6 458</b>	-	-	<b>9.1</b>	<b>34 172</b>	-
<b>All cancers excl. NMSC</b>	<b>12 164</b>	-	-	<b>15.5</b>	<b>6 412</b>	-	-	<b>9.0</b>	<b>33 632</b>	-

## Data source and methods

### Incidence

**Country-specific data source:** [ {"dt\_list": "National cancer registry"} ]

**Method:** National (or sub-national with coverage greater than 50%) rates projected to 2022



### Mortality

**Country-specific data source:** No data

**Method:** Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Prevalence

Computed using sex-; site- and age-specific incidence to 1-;3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

